Company
The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.
Rius Medical mission is to make its proprietary highly innovative platform available at year 2 to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.
Waldachtal, Baden-Württemberg, Germany
Send a message
English
English
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases, like type 1 diabetes by solving the problem of Drug Delivery through reprogramming stem cells.
On offer as Business-to-Business solution to France-based Erytech Pharma, Switzerland-based Orphan Technologies among others is upgraded red blood cells that do more than simply carry oxygen. For example...
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases, like type 1 diabetes by solving the problem of Drug Delivery through reprogramming stem cells.
On offer as Business-to-Business solution to France-based Erytech Pharma, Switzerland-based Orphan Technologies among others is upgraded red blood cells that do more than simply carry oxygen. For example Erytech Pharma’s therapeutic product (half-life 29 days) is undergoing clinical Phase III for pancreatic cancer and clinical Phase II for breast cancer. The Business Model is that of a provider/supplier of 120 days lifespan red blood cells against blood donation half-life 29 days red blood cells.
Rius Medical is seeking a 400,000 euro bridge financing for early start July 2021 onwards instead of December 2021 under EIC Pathfinder OPEN grant – supporting the exploration of bold ideas for radically new technologies. Rius Medical proposal has a convincing long-term vision of a radically new technology with a transformative positive effect to the economy and society.
An EXIT opportunity at year 2 for early investors joining this Series A investment round of up to 1 million euro and post-money valuation at 5 million euro will result in EUR 10,5 million financial benefits on TWO products at year 2. So 400,000 euro bridge financing against 8% ownership results in EUR 4,2 million financial benefits on TWO products by December 2022!
6
Followers
1
Like
Start in 31 August 2016
31 August 2016
registration with the commercial register of Stuttgart local court under folio HRB 757947
to be continued ...